Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical errors and supplements

This article was originally published in The Tan Sheet

Executive Summary

"It isn't easy to really identify and link an adverse reaction to a particular...drug/food, drug/supplement interaction," GAO Health Financing and Public Health Issues Associate Director Janet Heinrich states during a Feb. 1 Senate Health & Education Committee hearing held to discuss medical errors in the health care system. The remark came in response to a query from Sen. Christopher Dodd (D-Conn.) regarding interactions involving dietary supplements. Also testifying at the hearing, CDER Director Janet Woodcock, MD, commended a CVS program to alert consumers about possible Rx/OTC/supplement interactions, saying "the role of the pharmacist and the pharmacy has been underutilized in managing the safety of medications." TV and print ads for the CVS program broke in January (1"The Tan Sheet" Jan. 24, p. 8)

You may also be interested in...



CVS Drug Interaction System Provides Supplement/OTC/Rx Data

CVS is providing customers with information on interactions between nutritional supplements and OTC drugs with prescription medications via a new program. The company says it is the first drugstore chain to offer the service.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel